Historical background
• Aeronautics & Automative Industries : Total Quality Management, Design for Six-Sigma • FDA officials realized that biologics and drugs could also stand to benefit from QbD.
• Concept paper on 21st Century Good Manufacturing Practices.
• FDA produced a guidance document : « Pharmaceutical cGMPs for the 21st Century » • ICH published the Guideline document: Q8 (R2): Pharmaceutical Development.
• key and critical process parameters contributing to identification of a design space, which helps to provide an "assurance of quality." Proper execution of DoE within a design space is safe under QbD in bioprocess industries because work within a design space is not considered a change (1) . However, some pitfalls can lead to a poorly defined design space. They can come from unexpected results, failure to take account of variability (due to assay, operator, or raw material) within a process, and the choice of parameters and their ranges considered in an experimental study, as well as errors in statistical analysis (e.g., model selection, residual analysis, transformation of response). We present here some good industrial practices based on our experience, on literature for the application of a DoE approach in bioprocess industries, and on nonbiotechnological industrial approaches (e.g., the oil and chemical industries, in which DoE and similar statistical techniques have been applied for many years).
Setting "SMART" Objectives: It is In practice ?
T. Bastogne, "Quality-by-design of nanopharmaceuticals -A state of the art," Nanomedicine: Nanotechnology, Biology, and Medicine. June 2017.
• 
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Where in practice ? Nanoparticles were prepared using modified ionic gelation method, [21, 22] where CS was dissolved in 1% acetic acid solution to a various concentration and TPP was dissolved in distilled water with various concentrations, based on the results of preliminary study. RZT was uniformly dispersed in TPP solution and this solution was added drop-wise to CS solution under continuous stirring at room temperature. RZT CS nanoparticles formed based on the principle of electrostatic attraction between positively charged primary amino groups on CS chains and charged polyanions (TPP). RZT CS nanoparticles were centrifuged at 6000 rpm for 30 min (Remi R-88). The supernatant liquid was separated and nanoparticles were redispersed in PBS at pH 6.8 and ultrasonicated for 5 min to disaggregate the CS nanoparticles. Three nanoparticles optimized batches, 
Quality target product profile (QTPP) and risk analysis of RHT SLN
The QTPP is described as the quality properties that a drug product need to possess so as to fulfill the objectives set in target product profile as quantitative attributes. QTPP should furnish a quantitative surrogate to describe the aspects of clinical safety and efficacy by determining the CQA, CPP and control strategy (ICH, 2009).
In case of RHT SLN, QTPP is a lower size and PDI with lipidic core is expected to facilitate transport of drug across the nasal mucosal barriers both into the cerebral tissues and systemic circulation. Lower PDI is to reduce aggregation of particle during long term stability. Higher entrapment efficiency is to achieve higher drug loading in lipid matrix (Vora et al., 2013). The crucial step in risk assessment is to gather the entire responsible factor systematically that could influence the desired product quality. These factors were categorized hierarchically using an Ishikawa diagram (Fig.1) . The parameters summarized in Ishikawa diagram assisted in the identification of failure modes of SLN formulation. , predicted residual sum of square and graphically by 3D response surface plot provided by Design Expert software. The level of significance was considered at p-value < 0.05. The regression analysis, linear regression plots (observed versus predicted value) and Pareto chart of the dependent variables were plotted using MS-Excel. 
Data optimization and model validation

Design of Experiments
• Many inconsistencies between DoE methods and objectives
• A good software is necessary but not enough ! Expertise is needed
• Confidence of the results requires to apply strictly validation procedures.
• Only 5/30 papers have really implemented a cross-validation step And after ?
• The Design Space is not the ultimate goal. The last part of the QbD lifecyle is totally forgotten.
• No control strategy 
Conclusion
• The Quality-by-Design approach is more and more adopted in the nano-community mainly in India and USA.
• Nevertheless, some important parts, e.g. control strategy & quality management, are still ignored.
• Statistical tools exist but they are not always used correctly à educational effort is needed.
• QbD success relies on the synergistic relationships between chemists, physicists, biologists, statisticians and engineers.
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